CIK 0001693011
INZY Inozyme Pharma, Inc.
Insider trading from SEC Form 4. Last filing Jul 3, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Signals
Open-market buys and sells at Inozyme Pharma, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Douglas A Treco CEO & Chairman sell | $7,849 8,819 shares | -18% | - |
Transactions
The last 36 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2025 | Axel Bolte director | UTender of shares Common Stock | -423,926 | $4.00 | $1.7M | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Robert Lorne Hopfner director | UTender of shares Common Stockindirect: By Pivotal | -2,923,110 | $4.00 | $12M | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Sanjay Subramanian SVP, CFO & Head of BD | UTender of shares Common Stock | -39,701 | $4.00 | $159k | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Douglas A Treco CEO & Chairman | UTender of shares Common Stock | -43,861 | $4.00 | $175k | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Matthew Winton COO | UTender of shares Common Stock | -21,743 | $4.00 | $87k | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Lynne Marie Sullivan director | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,368 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Axel Bolte director | DDisposition to issuer Stock Option (Right to Buy)derivative | -234,176 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Sanjay Subramanian SVP, CFO & Head of BD | DDisposition to issuer Restricted Stock Unitsderivative | -38,500 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Matthew Winton COO | DDisposition to issuer Restricted Stock Unitsderivative | -41,500 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Douglas A Treco CEO & Chairman | DDisposition to issuer Restricted Stock Unitsderivative | -150,000 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Robert Lorne Hopfner director | UTender of shares Common Stockindirect: By Pivotal | -1,571,741 | $4.00 | $6.3M | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Douglas A Treco CEO & Chairman | DDisposition to issuer Stock Option (Right to Buy)derivative | -86,979 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Matthew Winton COO | DDisposition to issuer Stock Option (Right to Buy)derivative | -145,000 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Axel Bolte director | DDisposition to issuer Stock Option (Right to Buy)derivative | -159,187 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Sanjay Subramanian SVP, CFO & Head of BD | DDisposition to issuer Stock Option (Right to Buy)derivative | -180,000 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Douglas A Treco CEO & Chairman | DDisposition to issuer Stock Option (Right to Buy)derivative | -400,000 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Sanjay Subramanian SVP, CFO & Head of BD | DDisposition to issuer Stock Option (Right to Buy)derivative | -135,000 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Sanjay Subramanian SVP, CFO & Head of BD | DDisposition to issuer Stock Option (Right to Buy)derivative | -145,000 | - | - | 0 | Jul 3, 2025 |
| Jun 25, 2025 | Sanjay Subramanian SVP, CFO & Head of BD | AGrant or award Common Stock | +6,813 | $0.74 | $5,042 | 39,701 | Jun 27, 2025 |
| Jun 25, 2025 | Matthew Winton COO | AGrant or award Common Stock | +14,355 | $0.74 | $11k | 21,743 | Jun 27, 2025 |
| Jun 25, 2025 | Douglas A Treco CEO & Chairman | AGrant or award Common Stock | +2,815 | $0.74 | $2,083 | 43,861 | Jun 27, 2025 |
| May 15, 2025 | Axel Bolte director | MOption exercise Common Stock | +152,823 | $0.98 | $150k | 419,519 | May 20, 2025 |
| May 15, 2025 | Axel Bolte director | MOption exercise Common Stock | +4,407 | $0.98 | $4,319 | 423,926 | May 20, 2025 |
| May 15, 2025 | Axel Bolte director | MOption exercise Stock Option (right to buy)derivative | -152,823 | $0.00 | $0 | 0 | May 20, 2025 |
| May 15, 2025 | Axel Bolte director | MOption exercise Stock Option (right to buy)derivative | -4,407 | $0.00 | $0 | 0 | May 20, 2025 |
| Apr 1, 2025 | Douglas A Treco CEO & Chairman | MOption exercise Common Stock | +25,000 | - | - | 49,865 | Apr 3, 2025 |
| Apr 2, 2025 | Douglas A Treco CEO & Chairman | SOpen-market sale Common Stock | -8,819 | $0.89 | $7,849 | 41,046 | Apr 3, 2025 |
| Apr 1, 2025 | Douglas A Treco CEO & Chairman | MOption exercise Restricted Stock Unitsderivative | -25,000 | $0.00 | $0 | 50,000 | Apr 3, 2025 |
| Mar 31, 2025 | Sanjay Subramanian SVP, CFO & Head of BD | AGrant or award Common Stock | +2,490 | $0.77 | $1,917 | 32,888 | Apr 2, 2025 |
| Mar 31, 2025 | Matthew Winton COO | AGrant or award Common Stock | +2,490 | $0.77 | $1,917 | 7,388 | Apr 2, 2025 |
| Mar 11, 2025 | Douglas A Treco CEO | AGrant or award Stock Option (right to buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Mar 17, 2025 |
| Mar 11, 2025 | Matthew Winton COO | AGrant or award Stock Option (right to buy)derivative | +145,000 | $0.00 | $0 | 145,000 | Mar 17, 2025 |
| Mar 11, 2025 | Sanjay Subramanian SVP, CFO | AGrant or award Stock Option (right to buy)derivative | +145,000 | $0.00 | $0 | 145,000 | Mar 17, 2025 |
| Mar 11, 2025 | Douglas A Treco CEO | AGrant or award Restricted Stock Unitsderivative | +100,000 | $0.00 | $0 | 100,000 | Mar 17, 2025 |
| Mar 11, 2025 | Matthew Winton COO | AGrant or award Restricted Stock Unitsderivative | +41,500 | $0.00 | $0 | 41,500 | Mar 17, 2025 |
| Mar 11, 2025 | Sanjay Subramanian SVP, CFO | AGrant or award Restricted Stock Unitsderivative | +38,500 | $0.00 | $0 | 38,500 | Mar 17, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Axel Boltedirector
- Robert Lorne Hopfnerdirector, owner
- Sanjay SubramanianSVP, CFO & Head of BD
- Lynne Marie Sullivancfo, officer, director
- Douglas A TrecoCEO & Chairman
- Matthew WintonCOO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.